Immunomedics, Inc. (IMMU)
Stock Price:
$40.54 USD
0.54 (1.35%)
Updated Aug 12, 2020 2:20 PM EDT - Market open
Key Info
| Market Cap |
9.37B |
| Revenue (ttm) |
20.37M |
| Net Income (ttm) |
-353.41M |
| Shares Out |
231.14M |
| EPS (ttm) |
-1.70 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$40.54 |
| Previous Close |
$40.00 |
| Change ($) |
0.54 |
| Change (%) |
1.35% |
| Day's Open |
40.08 |
| Day's Range |
39.73 - 40.80 |
| Day's Volume |
772,997 |
| 52-Week Range |
8.80 - 44.91 |
More Stats
| Market Cap |
9.37B |
| Enterprise Value |
8.40B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
231.14M |
| Float |
204.66M |
| EPS (basic) |
-1.73 |
| EPS (diluted) |
-1.70 |
| FCF / Share |
-1.16 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
26.44M |
| Short Ratio |
11.00 |
| Short % of Float |
12.82% |
| Beta |
3.40 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
460.04 |
| PB Ratio |
16.82 |
| Revenue |
20.37M |
| Operating Income |
-313.00M |
| Net Income |
-353.41M |
| Free Cash Flow |
-260.44M |
| Net Cash |
965.74M |
| Net Cash / Share |
4.18 |
| Gross Margin |
-1,249.82% |
| Operating Margin |
-1,536.66% |
| Profit Margin |
-1,735.10% |
| FCF Margin |
-1,278.59% |
| ROA |
-25.16% |
| ROE |
-100.04% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (11)
| Buy |
9 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$52.24*
(28.86% upside)
Low
40.0
Current: $40.54
High
60.0
Target: 52.24
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.30 | - | 3.09 | 3.23 | 5.65 | 9.04 | 4.96 | 32.73 | 14.71 | 60.93 |
| Revenue Growth | - | - | -4.39% | -42.81% | -37.48% | 82.22% | -84.84% | 122.54% | -75.86% | - |
| Gross Profit | 0.30 | - | 2.61 | 2.07 | 5.39 | 7.51 | 4.57 | 32.31 | 14.29 | 59.97 |
| Operating Income | -325 | -145 | -79.15 | -59.01 | -46.22 | -35.58 | -11.42 | 1.44 | -17.91 | 33.93 |
| Net Income | -357 | -158 | -153 | -59.04 | -48.00 | -35.43 | -11.38 | 1.38 | -14.24 | 37.00 |
| Shares Outstanding | 194 | 189 | 105 | 94.77 | 93.31 | 84.63 | 78.04 | 75.48 | 75.31 | 75.20 |
| Earnings Per Share | -1.84 | -0.84 | -1.47 | -0.62 | -0.51 | -0.42 | -0.15 | 0.02 | -0.19 | 0.49 |
| Operating Cash Flow | -222 | -131 | -62.25 | -48.46 | -39.00 | -30.69 | -5.90 | 4.91 | -12.19 | -7.07 |
| Capital Expenditures | -6.85 | -11.21 | -1.84 | -2.23 | -0.92 | -0.38 | -0.60 | -0.57 | -0.61 | -0.68 |
| Free Cash Flow | -229 | -142 | -64.09 | -50.69 | -39.92 | -31.07 | -6.50 | 4.34 | -12.79 | -7.75 |
| Cash & Equivalents | 613 | 498 | 155 | 50.63 | 99.62 | 41.83 | 41.33 | 32.84 | 27.10 | 30.49 |
| Total Debt | 17.07 | 7.06 | 98.08 | 97.35 | 96.62 | - | - | - | - | - |
| Net Cash / Debt | 596 | 491 | 56.82 | -46.73 | 2.99 | 41.83 | 41.33 | 32.84 | 27.10 | 30.49 |
| Assets | 672 | 528 | 163 | 56.95 | 106 | 47.49 | 47.93 | 38.64 | 34.32 | 46.12 |
| Liabilities | 404 | 262 | 222 | 114 | 110 | 8.63 | 8.13 | 4.47 | 6.68 | 5.40 |
| Book Value | 268 | 267 | -58.69 | -56.82 | -3.91 | 39.35 | 40.18 | 34.46 | 27.82 | 40.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Immunomedics, Inc. |
| Country |
United States |
| Employees |
366 |
Stock Information
| Ticker Symbol |
IMMU |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: IMMU |
Description
Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively. The company focuses on commercializing sacituzumab govitecan as a third-line therapy for patients with metastatic triple-negative breast cancer in the United States. It also develops IMMU-140, a humanized antibody directed against an immune response target. Its other product candidates include products for the treatment of cancer and autoimmune diseases, including epratuzumab, an anti-CD22 antibody; veltuzumab, an anti-CD20 antibody; milatuzumab, an anti-CD74 antibody; and IMMU-114, a humanized anti-HLA-DR antibody. The company has clinical collaboration with AstraZeneca, MedImmune, and Roche; collaboration agreement with The Bayer Group; clinical and preclinical collaborations with academic cancer institutions; and research collaboration with the Memorial Sloan Kettering Cancer Center. It also has a partnership agreement with the Samsung BioLogics Co., Ltd. to manufacture hRS7, an Immunomedics proprietary humanized antibody; and a collaboration and license agreement with pH Pharma Co. Ltd. for the development and commercialization of multiple novel antibody-drug conjugates in oncology. The company was founded in 1982 and is headquartered in Morris Plains, New Jersey.